CEO Daniel Perez Buys 166,665 Shares at $38.93—A Steady Sign of Confidence at Hinge Health Inc.

Insider Buying at Hinge Health Signals Confidence

On February 12, 2026 the CEO and co‑founder, Daniel Perez, added 166,665 shares of Class A common stock to his portfolio. The purchase, executed at the close price of $38.93, coincides with a week in which the company’s share price surged 24.9 % from the prior week, reflecting fresh optimism after a strong Q4 2025 earnings release. Unlike the 166,670‑share buy a month earlier, this trade was made under a Rule 10b‑5‑1 trading plan, indicating a pre‑approved, systematic approach rather than a spontaneous move. For investors, such disciplined buying by the CEO can be interpreted as a signal that the top management believes the current valuation undervalues the firm’s growth trajectory.

What the Deal Means for the Stock

The transaction is modest relative to Perez’s holdings—he currently owns 35,470 Class A shares and 515,705 Class B shares, the latter convertible into roughly 9.5 million Class A shares. Adding 166,665 shares does not dramatically shift the ownership balance, but it does reinforce a pattern of incremental accumulation. In a company where the price‑earnings ratio sits at –3.41 and the market cap is $3.05 billion, the CEO’s steady purchasing could help mitigate volatility that often follows earnings revisions. Moreover, the timing—right after a positive earnings beat and a projection of $700 million revenue for H1 2026—aligns with the company’s strategic focus on expanding its virtual physical therapy platform, suggesting that management views the near‑term outlook favorably.

Perez Daniel Antonio: A Profile of Cautious Aggression

Perez’s trading history shows a blend of large‑volume sales and systematic buys. In December 2025 he sold 166,670 Class A shares at $48.50, then purchased 166,660 shares the same day at $0.00, an unusual zero‑price trade that likely reflects a stock‑option exercise or a rounding artifact. Over the past year, he has repeatedly sold sizeable blocks of Class B stock, converting the proceeds into cash or reinvesting in Class A shares. His most recent sale of 166,665 Class B shares in February 2026, followed by the purchase of 166,665 Class A shares, illustrates a consistent strategy: liquidate convertible holdings to free capital and then reinforce the primary share class. This pattern signals a cautious but confident stance, typical of founders who wish to maintain control while demonstrating commitment to shareholders.

Investor Takeaway

For shareholders, Perez’s continued buying under a Rule 10b‑5‑1 plan provides a reassuring benchmark: the CEO is not merely trading on short‑term price movements but is following a pre‑set plan that aligns with the company’s long‑term growth goals. While the trade is small relative to his total holdings, it dovetails with a positive earnings narrative and an upward revenue outlook for 2026. Consequently, the deal should be viewed as a subtle endorsement of Hinge Health’s prospects, offering a modest boost to confidence in an otherwise volatile health‑care sector.

Market Context

Hinge Health’s share price, trading at $39.47 on the close of February 11, is still 22 % below its 52‑week high of $62.18, reflecting the broader market’s cautious stance after a series of analyst downgrades. Nevertheless, the company’s projected H1 2026 revenue of $700 million, combined with a solid Q4 earnings run‑rate, positions it well against competitors. As the CEO’s buying activity continues, investors may watch for further accumulation as a barometer of insider confidence and potential upside.